Health Care & Life Sciences » Pharmaceuticals | La Jolla Pharmaceutical Co.

La Jolla Pharmaceutical Co. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
1,057.00
616.00
-
10,056
Cost of Goods Sold (COGS) incl. D&A
5.00
17.00
-
-
1,268.00
6,048
Gross Income
5.00
17.00
-
-
1,268.00
4,008
SG&A Expense
17,934.00
21,323.00
42,679.00
78,258.00
114,159.00
194,059
EBIT
17,939.00
21,340.00
41,969.00
78,372.00
115,427.00
190,051
Non Operating Income/Expense
4.00
27.00
57.00
187.00
624.00
-
Pretax Income
17,935.00
21,313.00
41,912.00
78,185.00
114,803.00
199,469
Consolidated Net Income
17,935.00
21,313.00
41,912.00
78,185.00
114,803.00
199,469
Net Income
17,935.00
21,313.00
41,912.00
78,185.00
114,803.00
199,469
Net Income After Extraordinaries
17,935.00
21,313.00
41,912.00
78,185.00
114,803.00
199,469
Net Income Available to Common
18,736.00
21,313.00
41,912.00
78,185.00
114,803.00
199,469
EPS (Basic)
41.24
2.00
2.68
4.54
5.41
7.85
Basic Shares Outstanding
454.30
10,667.00
15,651.00
17,228.00
21,215.00
25,422
EPS (Diluted)
41.24
2.00
2.68
4.54
5.41
7.85
Diluted Shares Outstanding
454.30
10,667.00
15,651.00
17,228.00
21,215.00
25,422
EBITDA
17,934.00
21,323.00
41,622.00
77,642.00
114,159.00
185,646
Preferred Dividends
801.00
-
-
-
-
-

About La Jolla Pharmaceutical

View Profile
Address
4550 Towne Centre Court
San Diego California 92121
United States
Employees -
Website http://www.lajollapharmaceutical.com
Updated 07/08/2019
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. LJPC-501 is the proprietary formulation for angiotensin II.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.